

References

1. US Food and Drug Administration. Decentralized Clinical Trials for Drugs, Biological Products, and Devices Guidance for Industry, Investigators, and Other Stakeholders: Draft Guidance. FDA; May 2023.
2. Hammond M, Stehlik J, Drakos S, et al. Bias in medicine: lessons learned and mitigation strategies. *J Am Coll Cardiol Basic Trans Science*. 2021;6(1):78-85.
3. Powsner S, Goebert D, Richmond SJ, Takeshita J. Suicide risk assessment, management, and mitigation in the emergency setting. *Focus*. 2023;21(1):11.
4. US Food and Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry: Draft Guidance. FDA; June 2023.
5. Targum S, Wedel PC, Robinson J, et al. A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of major depressive disorder. *J Psychiatr Res*. 2013;47(7):944-954.
6. Williams JB, Popp D, Kobak KA, Detke MJ. P-640 - the power of expectation bias. *Eur Psychiatry*. 2012;27(suppl 1):1.